NCI Objects To Fisher As Scientific Director Of NSABP, Threatens To Cut Off Funding
In Brief: Senate Cancer Coalition Hearing On Tamoxifin Planned for May 11; Bresnick Leads AACR
Fisher and Redmond Subject Of Misconduct Investigation; ORI
Herberman Outlines NSABP restructuring In Plan To NCI
DCT Advisors Approve Increased Spending On Trials Monitoring
Possible Breach of Patient Confidentially By Calif. Physician; NCI
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Tumors are able to form with no DNA mutations, fly study shows
- From clinician scientist to nonprofit CEO
